Physician profile
David Richards
NPI 1235129396
$1,598.44
in general payments reported to CMS, 2019-2025
28 companies · $52.28 in 2025
The $52.28 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $62.30 · 2021: $177 · 2022: $570 · 2023: $187 · 2024: $198 · 2025: $52.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.43 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $199.27 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $185.03 | 2019-2024 | |
| Exelixis INC. | $128.47 | 2022 | |
| Epizyme, INC. | $125.00 | 2022 | |
| Karyopharm Therapeutics INC. | $124.99 | 2023 | Xpovio |
| Celgene Corporation | $109.16 | 2019-2023 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $106.71 | 2019 | |
| Amgen INC. | $104.26 | 2019-2022 | |
| Revance Therapeutics, INC. | $61.09 | 2024 | Daxxify |
| Emmaus Medical, INC. | $58.05 | 2022-2023 | Endari |
| Pfizer INC. | $40.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $34.55 | 2019-2025 | Airsupra |
| Verastem, INC. | $31.64 | 2019-2020 | |
| Genzyme Corporation | $29.73 | 2019 | |
| Dendreon Pharmaceuticals LLC | $28.13 | 2024 | Provenge |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $26.74 | 2019-2025 | Trodelvy |
| Janssen Scientific Affairs, LLC | $26.43 | 2019 | |
| Mirati Therapeutics, INC. | $23.38 | 2024 | Krazati |
| Blueprint Medicines Corporation | $18.73 | 2025 | Ayvakit |
| Apellis Pharmaceuticals, INC. | $18.02 | 2024 | Empaveli |
| Octapharma USA, INC. | $17.11 | 2024 | Panzyga |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Janssen Biotech, INC. | $15.94 | 2023 | |
| Puma Biotechnology, INC. | $15.73 | 2024 | |
| Merck Sharp & Dohme LLC | $14.27 | 2019 | |
| Eisai INC. | $13.33 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $12.87 | 2019 | |
| Abbvie INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.